Triple negative breast cancer, new therapeutic options and future strategies
![](https://www.fondazionemichelangelo.org/wp-content/uploads/2022/12/AdobeStock_302042936-1536x922-2-1024x615.png)
Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a review published on Nature Reviews – Clinical Oncology highlights the state of the art therapy in triple-negative breast cancer
HER2+ and ER+ breast cancer, promising results with trastuzumab, pertuzumab and palbociclib
![](https://www.fondazionemichelangelo.org/wp-content/uploads/2022/12/AdobeStock_302042936-1536x922-1-1024x615.jpeg)
NA-PHER2 trial, coordinated by Michelangelo Foundation, shows their efficacy as neoadjuvant therapy, with a relevant effect on Ki67
Triple negative breast cancer, new data from Michelangelo Foundation’s NeoTRIP trial
![](https://www.fondazionemichelangelo.org/wp-content/uploads/2022/12/AdobeStock_235871936-1536x922-1-1024x615.jpeg)
Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did not increase the rate of pathological complete remission, mostly influenced by PD-L1 expression